within Pharmacolibrary.Drugs.ATC.L;

model L01XX53
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.08,
    adminDuration  = 600,
    adminMass      = 0.072,
    adminCount     = 1,
    Vd             = 0.112,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Vosaroxin is an experimental anticancer quinolone derivative acting as a topoisomerase II inhibitor. It was being developed for the treatment of acute myeloid leukemia (AML) but is not approved for use; development was discontinued after phase III trials did not meet efficacy endpoints.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with relapsed or refractory acute myeloid leukemia after intravenous administration.</p><h4>References</h4><ol><li>C M Nijenhuis, L Lucas, H Rosing, A D R Huitema, M Mergui-Roelvink, G C Jamieson, J A Fox, D R Mould, J H M Schellens, J H Beijnen,Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.,Investigational new drugs,2017<a href='https://pubmed.ncbi.nlm.nih.gov/28138829/'>https://pubmed.ncbi.nlm.nih.gov/28138829/</a></li><li>Ciara Freeman, Niamh Keane, Ronan Swords, Francis Giles,Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?,Expert opinion on pharmacotherapy,2013<a href='https://pubmed.ncbi.nlm.nih.gov/23688047/'>https://pubmed.ncbi.nlm.nih.gov/23688047/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XX53;
